Hydrophilic and hydrophobic polymeric benznidazole-loaded nanoparticles: Physicochemical properties and in vitro antitumor efficacy

Development and characterization of benznidazole nano- and microparticles: A new tool for pediatric treatment of Chagas disease?

“…It could be due to the formation of H-bonding between the N-H group of BNZ and the C=O group of the polymer. These findings are in agreement with those results reported by Lima et al [14] and dos Santos-Silva et al [27], who showed similar modifications of the FT-IR spectra of BNZ by interactions with other polymers [14,27].…”

“…Thus, the range of the sizes of Dh, before and after freeze-drying of NP, were found to be around 201-250 nm and 242-281 nm, respectively ( Table 1). The increase in particle sizes after freeze-drying was tiny with fs value of around 1, demonstrating the freeze-drying process did not lead to significant NP aggregation ( [27]. Moreover, the positively charged NP could be attached to the negatively charged epithelial mucin layer in the gastrointestinal tract which in turn would improve drug oral bioavailability [48].…”

“…Physicochemical properties of such formulations were discussed to determine their in-vitro and invivo efficacy [20]. In particular, BNZ nanoformulations including liposomal formulations [21][22][23][24], nanocrystals [25,26] and polymeric nanoparticles [27] were described in the last years. However, the only chemotherapeutic treatment available for Chagas disease, to these days, is based on tablets, an unsuitable dosage form to treat neonates and young children [28].…”

Effect of Dexamethasone-Loaded PLGA Nanoparticles on Oral Mucositis Induced by 5-Fluorouracil

“…The NPs were prepared by the solvent emulsification-evaporation method, according to a previously standardized nanoparticulate system, which consists of an organic and aqueous phase [ 34 ]. The aqueous phase (14 mL), containing the surfactant 0.5% w/v PVA in water, was filtered through 0.45 μm membranes [ 35 ]. The organic phase (6 mL) contained PLGA 0.5% w/v , and a 25:75 v/v ratio of dichloromethane and acetone was injected into the aqueous phase, with a burette, at 1 mL/min under magnetic stirring at 720 rpm and 25 °C.…”

“…The emulsification was carried out in Ultra-Turrax equipment (IKA Labortechnik, Staufen, Germany) with a stirring speed of 20,000 rpm for 18 min. The organic solvent was evaporated at 25 °C under magnetic stirring at 720 rpm overnight [ 35 ]. Different quantities of DEX were dissolved with the polymer in the organic phase to provide drug/copolymer ratios of 1:20, 1:10, and 1:2.5.…”